Abstract Library

#4513 Predictive value of different PD-L1 immunohistochemistry clones for immunotherapy efficacy in neuroendocrine tumours: A case series

Introduction: In the ZS001 clinical trial, we observed that NET patients with higher PD-L1 expression levels were more likely to benefit preferentially from immunotherapy.

Conference:

Presenting Author:

Authors: Sun Y, Zhang Q, Cao F, Huang X, Zhang P,

Keywords: neuroendocrine tumour, immunotherapy, PD-L1, SP142, 28-8, C0148, E1L3N,

#4394 Application of somatostatin receptor PET/CT in assisting preoperative lymph node evaluation and surgical decision-making for duodenal and pancreatic neuroendocrine neoplasms

Introduction: Preoperative precise staging of lymph nodes is crucial for determining surgical approach and extent for duodenal and pancreatic neuroendocrine neoplasms (DP-NENs), especially for small (≤2cm) DP-NENs.

Conference:

Presenting Author:

Authors: Xianze W, Bohui Y, Wenjia Z, Wensheng L, Meixi L,

Keywords: 68Ga-SSTR PET/CT, neuroendocrine neoplasm, lymph node metastasis, surgical decision-making,

#1545 In Vivo Expression of Survivin and XIAP in Medullary Thyroid Carcimoma

Introduction: Medullary thyroid carcinoma (MTC) accounts for approximately 5 % of all thyroid malignancies. Although surgery remains the first line therapy with curative intention, for advanced MTC current chemotherapeutic regimes do not provide promising results. Consequently, the identification of biologically relevant biomarkers that are associated with MTC progression may provide novel therapeutic targets.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Werner T

Authors: Werner T, Riemer J, Dizdar L, Wolf A, Cupisti K,

Keywords: MTC, IAP, survivin, XIAP,